Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. In developed countries, it is one of the main causes of non-traumatic permanent disability in early adulthood. Nearly 85% of MS-patients evolve by relapses, having the relapse-remitting (RR) form of the disease. Disease-modifying treatment (DMT) includes immunomodulatory drugs, mainly injectable, which have proved to reduce the number of relapses and disability progression [1].Glatiramer acetate [...]